The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials

被引:7
作者
Qiu, Jingyue [1 ]
Sheng, Dandan [1 ]
Lin, Fei [2 ,3 ]
Jiang, Peng [4 ]
Shi, Ning [1 ]
机构
[1] PLA Strateg Support Force Med Ctr, Pharmaceut Dept, Beijing, Peoples R China
[2] Chengdu Med Coll, Dept Pharm, Affiliated Hosp 1, Chengdu, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu, Peoples R China
[4] PLA Strateg Support Force Integrated Training Team, Med Team, Beijing, Peoples R China
关键词
CDK4; 6; inhibitor; trilaciclib; chemotherapy; myelosuppression; meta-analysis; CELL LUNG-CANCER; RISK;
D O I
10.3389/fphar.2023.1157251
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Trials Registry Platform were searched up to 25 October 2022. Only randomized controlled trials (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus chemotherapy for treating malignant cancers in adult patients were included. The primary outcome included the incidence of SN, FN, the DSN, and administration of ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes included the risk of adverse events (AEs) and severe adverse events (SAEs).Results: In total, four randomized controlled trials (RCTs) involving 345 patients with SCLC or breast cancer were included in this meta-analysis. Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was also statistically lower in the experimental group than in the control group. Meanwhile, the ORR, overall survival, and progress-free survival of the two groups were identical, and no negative impact of Trilaciclib on the clinical outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and vomiting were identical regardless of Trilaciclib usage.Conclusion: Trilaciclib demonstrated its efficacy in reducing the occurrence of chemotherapy-induced myelosuppression and utilization of supportive care interventions without undermining the clinical benefits of chemotherapy regimens during treatment with an acceptable safety profile.
引用
收藏
页数:10
相关论文
共 19 条
  • [1] Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
    Bianchini, Giampaolo
    De Angelis, Carmine
    Licata, Luca
    Gianni, Luca
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) : 91 - 113
  • [2] Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
    Bohlius, Julia
    Bohlke, Kari
    Castelli, Roberto
    Djulbegovic, Benjamin
    Lustberg, Maryam B.
    Martino, Massimo
    Mountzios, Giannis
    Peswani, Namrata
    Porter, Laura
    Tanaka, Tiffany N.
    Trifiro, Gianluca
    Yang, Hushan
    Lazo-Langner, Alejandro
    [J]. BLOOD ADVANCES, 2019, 3 (08) : 1197 - 1210
  • [3] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Crawford, Jeffrey
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong Khanh
    Garcia, Jacob
    Barron, Richard
    Lyman, Gary H.
    [J]. SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932
  • [4] CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
    Deng, Jiehui
    Wang, Eric S.
    Jenkins, Russell W.
    Li, Shuai
    Dries, Ruben
    Yates, Kathleen
    Chhabra, Sandeep
    Huang, Wei
    Liu, Hongye
    Aref, Amir R.
    Ivanova, Elena
    Paweletz, Cloud P.
    Bowden, Michaela
    Zhou, Chensheng W.
    Herter-Sprie, Grit S.
    Sorrentino, Jessica A.
    Bisi, John E.
    Lizotte, Patrick H.
    Merlino, Ashley A.
    Quinn, Max M.
    Bufe, Lauren E.
    Yang, Annan
    Zhang, Yanxi
    Zhang, Hua
    Gao, Peng
    Chen, Ting
    Cavanaugh, Megan E.
    Rode, Amanda J.
    Haines, Eric
    Roberts, Patrick J.
    Strum, Jay C.
    Richards, William G.
    Lorch, Jochen H.
    Parangi, Sareh
    Gunda, Viswanath
    Boland, Genevieve M.
    Bueno, Raphael
    Palakurthi, Sangeetha
    Freeman, Gordon J.
    Ritz, Jerome
    Haining, W. Nicholas
    Sharpless, Norman E.
    Arthanari, Haribabu
    Shapiro, Geoffrey I.
    Barbie, David A.
    Gray, Nathanael S.
    Wong, Kwok-Kin
    [J]. CANCER DISCOVERY, 2018, 8 (02) : 216 - 233
  • [5] Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
    Domine Gomez, Manuel
    Csoszi, Tibor
    Jaal, Jana
    Kudaba, Iveta
    Nikolov, Krasimir
    Radosavljevic, Davorin
    Xiao, Jie
    Horton, Janet K.
    Malik, Rajesh K.
    Subramanian, Janakiraman
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (07) : 1463 - 1472
  • [6] Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers
    Epstein, Robert S.
    Weerasinghe, Roshanthi K.
    Parrish, Amy S.
    Krenitsky, JoAnn
    Sanborn, Rachel E.
    Salimi, Tehseen
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 108 - 118
  • [7] Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
    Epstein, Robert S.
    Aapro, Matti S.
    Roy, Upal K. Basu
    Salimi, Tehseen
    Krenitsky, JoAnn
    Leone-Perkins, Megan L.
    Girman, Cynthia
    Schlusser, Courtney
    Crawford, Jeffrey
    [J]. ADVANCES IN THERAPY, 2020, 37 (08) : 3606 - 3618
  • [8] Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
    Ferrarotto, Renata
    Anderson, Ian
    Medgyasszay, Balazs
    Garcia-Campelo, Maria Rosario
    Edenfield, William
    Feinstein, Trevor M.
    Johnson, Jennifer M.
    Kalmadi, Sujith
    Lammers, Philip E.
    Sanchez-Hernandez, Alfredo
    Pritchett, Yili
    Morris, Shannon R.
    Malik, Rajesh K.
    Csoszi, Tibor
    [J]. CANCER MEDICINE, 2021, 10 (17): : 5748 - 5756
  • [9] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
    Goldman, Jonathan W.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Garassino, Marina Chiara
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowicz, Andrzej
    Losonczy, Gyorgy
    Conev, Nikolay V.
    Armstrong, Jon
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Jiang, Haiyi
    Paz-Ares, Luis
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 51 - 65
  • [10] Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
    Hart, Lowell L.
    Ferrarotto, Renata
    Andric, Zoran G.
    Beck, J. Thaddeus
    Subramanian, Janakiraman
    Radosavljevic, Davorin Z.
    Zaric, Bojan
    Hanna, Wahid T.
    Aljumaily, Raid
    Owonikoko, Taofeek K.
    Verhoeven, Didier
    Xiao, Jie
    Morris, Shannon R.
    Antal, Joyce M.
    Hussein, Maen A.
    [J]. ADVANCES IN THERAPY, 2021, 38 (01) : 350 - 365